Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Anderson (Glasgow, United Kingdom), S. Briggs (Glasgow, United Kingdom), A. Mckay (Glasgow, United Kingdom), S. Mccluskey (Glasgow, United Kingdom), A. Wright (Glasgow, United Kingdom), G. Chalmers (Glasgow, United Kingdom). Survival on antifibrotic therapy in IPF – the impact of pleural plaques, concomitant emphysema and definite vs possible UIP. 1340

Member's Comments

No comment yet.

Related content which might interest you: Effect of metformin on clinically relevant outcomes in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – ILDs: clinical aspects Year: 2017 Histology and pathogenesis of usual interstitial pneumonia (UIP) versus nonspecific interstitial pneumonia (NSIP): progressive remodeling or resolution and healing? Source: Annual Congress 2006 - Usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP), idiopathic or not: new concepts in diagnosis and treatment Year: 2006 Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment Source: International Congress 2016 – IPF treatment I Year: 2016 MUC5B genotype affects survival of patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia Year: 2019 Corticosteroids determine clinical course of IIPs with possible UIP HRCT pattern? Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 Idiopathic pulmonary fibrosis (IPF) and idiopathic nonspecific interstitial pneumonia (NSIP): what treatment and for whom? Source: Annual Congress 2006 - Usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP), idiopathic or not: new concepts in diagnosis and treatment Year: 2006 Analysis of baseline characteristics by emphysema extent in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – ILDs: clinical aspects Year: 2017 Warfarin and survival in people with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2007; 30: Suppl. 51, 246s Year: 2007 Idiopathic pulmonary fibrosis - IPF Source: Respipedia Article Year: 2018 Histopathological assessment and classification Source: Annual Congress 2006 - PG8 - Interstitial lung diseases: idiopathic interstitial pneumonias Year: 2006 Therapeutic options and management of pulmonary fibrosis: old and new Source: Annual Congress 2005 - PG15 - Therapeutic options for interstitial lung diseases in 2005 Year: 2005 Neutrophil-rich inflammation in induced sputum of patients with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2001; 18: Suppl. 33, 409s Year: 2001 Osteoporosis treatment effectiveness in patient with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Towards a better diagnosis of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2010 - Idiopathic pulmonary fibrosis: present understandings and future directions Year: 2010 Benefit of continued pirfenidone treatment following hospitalisation within the first 6 months of therapy—Ad hoc analysis from three phase 3 trials in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015 High short-term mortality following lung biopsy for usual interstitial pneumonia Source: Eur Respir J 2001; 17: 175-179 Year: 2001 Lysozyme level and activity are decreased in the lungs of patients with idiopathic pulmonary fibrosis (IPF) and potentially contribute to increased susceptibility to pulmonary infection Source: Annual Congress 2006 - Usefulness of broncoalveolar lavage (BAL) in interstitial lung diseases Year: 2006 Long-term nintedanib treatment in idiopathic pulmonary fibrosis (IPF): new data from INPULSIS-ON Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017 Estimating long-term survival in progressive fibrosing interstitial lung disease (PF-ILD) other than IPF using matched IPF data Source: Virtual Congress 2021 – Exploring the phenotypic heterogeneity across rare diffuse parenchymal lung diseases Year: 2021